Advertisement

Clinical and Translational Oncology

, Volume 21, Issue 12, pp 1781–1785 | Cite as

Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status

  • C. CarrilesEmail author
  • P. Jimenez-Fonseca
  • M. Sánchez-Cánovas
  • P. Pimentel
  • A. Carmona-Bayonas
  • T. García
  • M. Carbajales-Álvarez
  • A. Lozano-Blázquez
Brief Research Article

Abstract

Introduction

Our aim was to assess efficacy and safety and prognostic factors associated with TAS-102 in clinical practice.

Method

Retrospective, multicenter, and observational study including patients with advanced refractory colorectal cancer who started TAS-102 between March 2016 and August 2018. The primary end point was overall survival (OS). Secondary end points included progression-free survival, toxicity and analyze prognostic factors present at the beginning of TAS-102.

Result

84 patients were evaluable. The median OS was 8.30 (95% CI 6.23–9.87) months and PFS was 2.62 (95% CI 2.36–3.05) months. In multivariate analysis, ECOG 0 and reduced dose combined with more cycles were associated with better prognosis. Patients with an ECOG > 0 had worse prognosis (HR 3.34, 95% CI 1.09–10.27, p = 0.035). 95.2% experienced some type of adverse effect and 45.2% had grade ≥ 3 toxicities.

Conclusion

Results suggest reconsidering TAS-102 in patients with ECOG > 0, something that should be investigated in prospective randomized clinical trials.

Keywords

ECOG Multivariate PROGNOSIS Progression-free survival Survival Toxicity 

Notes

Acknowledgements

The authors are grateful for the statistical analysis to the Unidad de Consultoría Estadística de los Servicios Científico-Técnicos de la Universidad de Oviedo.

Funding

This is an academic study supported by the authors.

Compliance with ethical standards

Conflict of interest

The authors declare that they do not have any conflict of interest that may inappropriately influence this work.

Ethical statement

The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This study is an observational, non-interventionist trial.

Informed consent

Signed informed consent was obtained from all patients.

References

  1. 1.
    Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cáncer. Ann Oncol. 2016;27:1386–422.CrossRefGoogle Scholar
  2. 2.
    Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controled, phase 3 trial. Lancet. 2013;381:303–12.CrossRefGoogle Scholar
  3. 3.
    Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A, et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumors. Br J Cancer 2012;107:429-34.CrossRefGoogle Scholar
  4. 4.
    Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–19.CrossRefGoogle Scholar
  5. 5.
    Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica trifluridina/tiperacilo (Lonsurf®). Consultada [2/2019]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/1161096001/FT_1161096001.pdf.
  6. 6.
    Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, et al. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Clin Transl Oncol. 2017;19:227–35.CrossRefGoogle Scholar
  7. 7.
    Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, et al. Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: A Multicenter Register in the frame of the Italian Compassionate Use Program. Oncologist. 2018;23:1–10.CrossRefGoogle Scholar
  8. 8.
    Sforza V, Martinelli E, Cardone C, Martini G, Napolitano S, Vitiello PP, et al. Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open. 2017;2:e000229.CrossRefGoogle Scholar
  9. 9.
    Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, et al. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. Clin Colorectal Cancer. 2016;15:e109–e115115.CrossRefGoogle Scholar
  10. 10.
    Unseld M, Drimmel M, Siebenhüner A, Gleiss A, Bianconi D, Kieler M, et al. Optimizing treatment sequence for late-line metastatic colorectal cancer patients using Trifluridine/Tipiracil and Regorafenib. Clin Colorectal Cancer. 2018;17(4):274–9.CrossRefGoogle Scholar
  11. 11.
    Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, et al. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Int J Clin Oncol. 2018;23:482–9.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.Department of PharmacyHospital Universitario Central de AsturiasOviedoSpain
  2. 2.Department of Medical OncologyHospital Universitario Central de AsturiasOviedoSpain
  3. 3.Department of Hematology and Medical OncologyHospital Universitario Morales Meseguer, UMU, IMIBMurciaSpain
  4. 4.Department of Medical OncologyHospital Universitario Santa LucíaCartagenaSpain

Personalised recommendations